vascular risk factor. 2 Despite the overwhelming epidemiological evidence, the pathogenesis of accelerated atherosclerosis even in early stages of renal impairment is only poorly understood. In this issue of American Journal of Hypertension, Fujii et al. 3 report an interesting study in which they strengthen the notion that the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) might be the crucial link between renal and cardiovascular disease. They determined coronary flow velocity reserve (CFVR) using adenosine stress Doppler echocardiography in 66 hypertensive patients with and without renal impairment. Aside from classical cardiovascular risk factors, intima-media thickness and pulse wave velocity were also measured. Not only was a decreased glomerular filtration rate (GFR) mirrored by an impaired CFVR, but also was ADMA an "independent" clinical parameter associated with both estimated GFR and CFVR. This has to be interpreted with caution as the authors excluded age from their multivariate analysis. Unfortunately, despite using a high-performance liquid chromatographybased method to measure ADMA, the authors did not provide data on ADMA's structural isomer symmetric dimethylarginine, which has also been linked to renal and coronary artery disease. 4 The concept of coronary flow reserve (CFR) was developed to describe the flow increase available to the heart in response to an increase in oxygen demand. CFR was expressed as the ratio between the maximal hyperemic flow and resting flow. A pressure drop across a stenosis causes compensatory vasodilation at rest, resulting in a diminished capability of the coronary circulation to adapt to an increase in oxygen demand. Therefore, a stenosis within the coronary artery results in a reduction of CFR. CFVR measured by Doppler ultrasound was introduced as a surrogate for CFR and was first measured during open heart surgery by applying Doppler suction probes to epicardial arteries for stenosis evaluation. 5 The development of intracoronary catheters and Doppler velocity sensor-equipped guidewires allowed the application of CFVR during catheterization procedures. 6 The results of this study by Fujii et al. are in line with a previous report which showed that treatment with the angiotensin-converting enzyme (ACE) inhibitor temocrapil lowered ADMA serum concentrations and improved CFVR beyond its blood pressure lowering effect in type 2 diabetic patients. Furthermore, the study by Kawata et al. 7 revealed a strong correlation between changes in ADMA concentrations and in CFVR after ACE inhibitor treatment. In addition to this previous study, the present work by Fujii et al. 3 demonstrated for the first time the link between ADMA as a parameter associated with both estimated GFR and CFVR.
Is the estimated GFR a marker of CFR and are both linked by ADMA? Despite all the limitations of this nonrandomized, uncontrolled cross-sectional study, which does not allow conclusions on cause and effect, the authors point out a potentially important pathway, by which renal injury and heart disease could be linked. The complex interplay of cardiac and renal disease is unlikely to be explained by a single gene, mechanism, or mediator. However, the endogenous NOS inhibitor ADMA seems not only to be a marker of the cardiorenal interplay but may also represent an important avenue for therapeutic interventions. Until these therapies are available, estimation of GFR using the Cockroft-Gault or the Modification of Diet in Renal Disease Study formula, as well as screening for microalbuminuria should become standard of care in patients at increased risk for or with overt cardiovascular disease.
